Hdac6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation

HIGHLIGHTS

• who: Tahiyat Alothaim from the DepartmentTechnological University have published the paper: HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation, in the Journal: Scientific Reports Scientific Reports
• how: The study suggested that HDAC6 inhibitors can be used as therapeutic adjuvants of cysteine deprivation to treat various non-mesenchymal breast cancers.

SUMMARY

The authors further confirmed that tubacin induced synthetic-lethal cell death in non-mesenchymal MDA-MB-436 and HCC70 cells when cotreated with either cysteine deprivation or erastin; Either tubucin or erastin alone had no significant . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.